Pediatric liver transplant in the U.S. has already surpassed 200 transplants in 2023, while long term survival and complications vary sharply by indication, center practices, and perioperative care. Outside the operating room, global pressure is rising too as cirrhosis, alcohol associated liver disease, and hepatocellular carcinoma continue to increase the demand for transplantation. This post brings those survival, graft, and cost figures together so you can see exactly where outcomes are holding steady and where they are slipping.
Key Takeaways
- In 2023, pediatric liver transplant recipients in the U.S. totaled 200+ transplants (OPTN pediatric reporting)
- In a nationwide U.S. analysis, pediatric liver transplant waiting list deaths were approximately 5–10% of waitlisted children per year depending on age band and MELD-P (registry study)
- Median 1-year patient survival after liver transplant in Eurotransplant programs is approximately 85–90% (reported in Eurotransplant outcomes summaries)
- For patients transplanted for HCC, many centers report 5-year post-transplant survival around 60–70% depending on selection criteria (systematic review range)
- In a large U.S. registry analysis (2002–2013), 5-year survival after liver transplant was about 70%
- Global demand is driven by an estimated 1.8 million people worldwide living with cirrhosis who may require transplantation eventually
- Alcohol-associated liver disease caused about 0.9 million deaths globally in 2019
- Nonalcoholic fatty liver disease affected 1/4 of the global population (25%) in a 2016 meta-analysis estimate
- The global liver transplant market was valued at about $8–10 billion in 2023 depending on scope (transplant services + related diagnostics)
- In the U.S., the annual cost of liver transplant-related care can exceed $200,000 per recipient in the year of transplant (cost-effectiveness and claims analyses)
- The cost of immunosuppressive therapy after liver transplant can exceed $20,000 per year per patient (pharmacy budget estimates in payer studies)
- The MELD score is used in the U.S. allocation system; each integer point change in MELD corresponds to a measurable increase in mortality risk (allocation model calibration)
- Approximately 20–25% of deceased donor livers are lost to discard in many analyses due to quality, logistics, or recipient factors (systematic reviews and allocation studies)
- A randomized trial of ex vivo normothermic oxygenated perfusion reported improved early allograft function (e.g., reduced peak ALT/AST) versus controls (quantified biomarker results)
With 200 plus US pediatric transplants in 2023 and 85 to 90% one year survival, demand driven by cirrhosis stays high.
Related reading
01 · Category
Transplant Volume2 stats
01
In 2023, pediatric liver transplant recipients in the U.S. totaled 200+ transplants (OPTN pediatric reporting)
02
In a nationwide U.S. analysis, pediatric liver transplant waiting list deaths were approximately 5–10% of waitlisted children per year depending on age band and MELD-P (registry study)
Interpretation
Transplant Volume Interpretation
In 2023, U.S. pediatric liver transplant volume reached over 200 transplants, and despite this level of activity, a nationwide registry analysis shows that each year 5 to 10 percent of waiting children died, underscoring that volume alone has not eliminated ongoing waitlist risk.
02 · Category
Clinical Outcomes18 stats
01
Median 1-year patient survival after liver transplant in Eurotransplant programs is approximately 85–90% (reported in Eurotransplant outcomes summaries)
02
For patients transplanted for HCC, many centers report 5-year post-transplant survival around 60–70% depending on selection criteria (systematic review range)
03
In a large U.S. registry analysis (2002–2013), 5-year survival after liver transplant was about 70%
04
A Cochrane review found that early post-transplant interventions (e.g., surgical technique and perioperative management) can improve graft and patient outcomes versus later rescue strategies, with survival effects depending on intervention type
05
Hospital mortality after liver transplant in the U.S. is around 5–8% (observational cohort estimates in major registry analyses)
06
Primary graft non-function occurs in roughly 3–5% of liver transplants in contemporary series
07
In a meta-analysis, the rate of post-transplant major vascular complications is about 5–10% (pooled cohort estimates)
08
The incidence of post-transplant diabetes mellitus is about 20–30% within the first year in many cohort studies
09
Cytomegalovirus (CMV) disease after transplant occurs in about 10–20% of recipients depending on donor/recipient serostatus and prophylaxis strategy (systematic review estimate)
10
In a large systematic review, 30-day mortality after liver transplant was about 2–6% depending on era and definitions
11
For living donor liver transplantation, 1-year graft survival is commonly reported around 90%+ in comparative studies
12
Recurrent HBV after liver transplant without prophylaxis can exceed 50% historically; with modern prophylaxis it drops below 10% in cohorts (reviewed evidence)
13
In a systematic review, retransplantation due to ischemic-type biliary lesions has an incidence around 1–3% (pooled studies)
14
Within 30 days after liver transplant, infection rates are frequently reported around 20–30% (systematic review of postoperative infections)
15
In a meta-analysis, 1-year graft survival after liver transplant was reported around 85–90% (pooled registry and trial data)
16
Acute kidney injury occurs in about 20–50% of liver transplant recipients depending on definitions (systematic review estimate)
17
Post-transplant renal dysfunction requiring dialysis occurs in roughly 2–10% of recipients in contemporary cohorts (registry-based estimates)
18
Long-term survival declines over time: pooled estimates show 10-year patient survival around ~50–60% (registry meta-analysis)
Interpretation
Clinical Outcomes Interpretation
Overall clinical outcomes after liver transplant are generally favorable, with about 85 to 90% 1-year patient survival in Eurotransplant and pooled data, yet the risk profile remains substantial as complications and adverse events persist, including around 20 to 30% post-transplant infection rates and a fall to roughly 50 to 60% 10-year survival.
03 · Category
Disease Drivers6 stats
01
Global demand is driven by an estimated 1.8 million people worldwide living with cirrhosis who may require transplantation eventually
02
Alcohol-associated liver disease caused about 0.9 million deaths globally in 2019
03
Nonalcoholic fatty liver disease affected 1/4 of the global population (25%) in a 2016 meta-analysis estimate
04
Estimated annual incidence of hepatocellular carcinoma is ~900,000 new cases worldwide
05
In the U.S., approximately 3.5 million people have cirrhosis (2018–2022 estimates summarized by major U.S. clinical literature)
06
NASH prevalence in the U.S. adult population is about 3–5% in pooled estimates
Interpretation
Disease Drivers Interpretation
From a Disease Drivers perspective, the pipeline to liver transplantation is being fueled by large, ongoing disease burdens, including about 1.8 million people worldwide living with cirrhosis who may eventually need a transplant alongside roughly 900,000 new hepatocellular carcinoma cases each year.
More related reading
04 · Category
Market Economics11 stats
01
The global liver transplant market was valued at about $8–10 billion in 2023 depending on scope (transplant services + related diagnostics)
02
In the U.S., the annual cost of liver transplant-related care can exceed $200,000per recipient in the year of transplant (cost-effectiveness and claims analyses)
03
The cost of immunosuppressive therapy after liver transplant can exceed $20,000per year per patient (pharmacy budget estimates in payer studies)
04
Costs for treatment of post-transplant biliary complications can add tens of thousands of dollars per case in U.S. claims databases (health economics studies)
05
The cost-effectiveness threshold frequently used in U.S. studies is $50,000–$100,000 per QALY (framework applied in transplant economic evaluations)
06
Living donor liver transplant avoids deceased donor allocation limits; transplant centers report that living donor programs can increase transplantable volume by 1–2 procedures per center per year in mature programs (program capacity reports)
07
In a U.S. claims study, the mean total 1-year healthcare cost after liver transplant exceeded $150,000per patient
08
In the U.S., median hospital charges for liver transplantation episodes can exceed $250,000per case (hospital charge analyses)
09
In Germany, statutory health insurance covers organ transplantation under SGB V with costs reimbursed at DRG rates (German reimbursement rule base)
10
Globally, immunosuppression medication spending for transplant patients is one of the largest components of post-liver transplant cost (review estimates)
11
In a multicenter study, cost savings from using more efficient allocation strategies (e.g., MELD-based allocation) are realized through reduced deaths on the waitlist and fewer emergency transplants
Interpretation
Market Economics Interpretation
In market economics for liver transplants, the price tag is substantial and growing, with U.S. post transplant care often exceeding $200,000 in the transplant year and immunosuppressive therapy alone surpassing $20,000 per patient annually, so allocation and efficiency gains that reduce waitlist deaths can produce meaningful cost impact.
05 · Category
Industry Trends13 stats
01
The MELD score is used in the U.S. allocation system; each integer point change in MELD corresponds to a measurable increase in mortality risk (allocation model calibration)
02
Approximately 20–25% of deceased donor livers are lost to discard in many analyses due to quality, logistics, or recipient factors (systematic reviews and allocation studies)
03
A randomized trial of ex vivo normothermic oxygenated perfusion reported improved early allograft function (e.g., reduced peak ALT/AST) versus controls (quantified biomarker results)
04
Ischemia-reperfusion injury is quantified by peak aminotransferases; reducing peak AST/ALT is a commonly reported endpoint in preservation studies
05
The U.S. Organ Procurement and Transplantation Network (OPTN) contains 58 organ procurement organizations (OPOs)
06
A 2021 study estimated that 15–20% of candidates on transplant lists may become too sick or die while waiting, depending on region and MELD dynamics (registry analyses)
07
Hepatocellular carcinoma recurrence after transplant is reduced by more stringent selection and bridging; selection criteria such as Milan criteria are associated with lower recurrence (meta-analysis with quantified recurrence rates)
08
AASLD guidelines recommend direct-acting antiviral therapy to treat HCV pre- or post-transplant to reduce HCV recurrence; sustained virologic response rates exceed 95% (DAA trial outcomes)
09
In pre-2015 era cohorts, 90-day mortality after liver transplant ranged around 7–12%; more recent standardized care has improved outcomes (registry trend analyses)
10
Living donor liver transplant rates in experienced centers can be 10–30% of all liver transplants in that center depending on region (program-level reports)
11
In the U.S. UNOS policy, MELD exception points for HCC are granted based on standardized criteria; typical modeled 3-month mortality categories are reflected in MELD exception updates (policy documentation)
12
In a 2022 cohort, uptake of direct-acting antiviral therapy among waitlist patients in transplant programs reached >80% where available (program studies)
13
In a 2018 systematic review, extended-criteria donor livers (ECD) used with selection strategies had acceptable early outcomes with measurable improvements in recipient survival compared with discard (meta-analysis quantifies survival)
Interpretation
Industry Trends Interpretation
Industry trends in liver transplantation show that survival and organ efficiency hinge on measurable risk changes and better preservation and therapy, with MELD score differences tracking mortality risk by each integer point and protocols helping cut early discard to about 20–25% while DAA uptake for HCV waitlist patients exceeds 80% in 2022 and living donor programs can make up 10–30% of transplants in experienced centers.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Liver Transplant Statistics. Gitnux. https://gitnux.org/liver-transplant-statistics
MLA
Margot Villeneuve. "Liver Transplant Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/liver-transplant-statistics.
Chicago
Margot Villeneuve. 2026. "Liver Transplant Statistics." Gitnux. https://gitnux.org/liver-transplant-statistics.
Sources & references
50 datasets cited across this report · attribution is report-level
+38 additional datasets cited (not shown individually)